<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364804</url>
  </required_header>
  <id_info>
    <org_study_id>24-20</org_study_id>
    <nct_id>NCT02364804</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer</brief_title>
  <official_title>A Study to Evaluate the Efficacy of Anti-emetic Drug Aprepitant Upon the Combination Chemotherapy of Nedaplatin and Docetaxel for Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiga University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiga University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of anti-emetic drug Aprepitant upon the&#xD;
      combination chemotherapy of nedaplatin and docetaxel for non-small cell lung cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy of anti-emetic drug Aprepitant upon the&#xD;
      combination chemotherapy of nedaplatin and docetaxel for non-small cell lung cancer (NSCLC).&#xD;
      The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in&#xD;
      patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of&#xD;
      nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed&#xD;
      retrospectively in patients who had received the combination chemotherapy with anti-emetic&#xD;
      agents except Aprepitant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of anti-emetic drug efficacy: Incidence and grade of nausea/vomiting</measure>
    <time_frame>Fifteen days after beginning of each cycle of chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence on clinical outcome: Survival</measure>
    <time_frame>Participants will be followed for 3 years after the last treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.</description>
    <other_name>Emend</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Non-small cell lung cancer patients who receive the combination chemotherapy of nedaplatin&#xD;
        and docetaxel&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who receive the combination chemotherapy of nedaplatin and docetaxel as a&#xD;
             treatment or an adjuvant therapy for non-small cell lung cancer.&#xD;
&#xD;
          2. ECOG performance status 0-1.&#xD;
&#xD;
          3. Aged 20-79 years old.&#xD;
&#xD;
          4. Laboratory values as follows 4000/mm3 &lt; WBC &lt; 12000/mm3, neutrophil count &gt; 2000/mm3,&#xD;
             platelet count &gt; 100000/mm3, hemoglobin &gt; 9.5g/dL, asparate transaminase &lt; 2.5 X&#xD;
             cutoff value, alanine transaminase &lt; 2.5 X cutoff value, total bilirubin &lt; 1.5g/dL,&#xD;
             Serum creatinine &lt; cutoff value, PaO2 &gt; 60 Torr.&#xD;
&#xD;
          5. Able and willing to give valid written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy against polysorbert 80 or platinum-containing drugs.&#xD;
&#xD;
          2. Severe complications (i.e. ischemic heart diseases required treatment, arrhythmia,&#xD;
             myocardial infarction within 6 months, liver cirrhosis, uncontrolled diabetes, and&#xD;
             hemorrhagic tendency).&#xD;
&#xD;
          3. Active and uncontrolled infectious disease.&#xD;
&#xD;
          4. Massive pleural or pericardial effusion.&#xD;
&#xD;
          5. Other malignancy requiring treatment.&#xD;
&#xD;
          6. Active interstitial pneumonitis or its past historyBreastfeeding and Pregnancy (woman&#xD;
             of child bearing potential)&#xD;
&#xD;
          7. Peripheral nerve disorder.&#xD;
&#xD;
          8. Pregnant or lactating women.&#xD;
&#xD;
          9. Concurrent administration of pimozide.&#xD;
&#xD;
         10. Decision of unsuitableness by principal investigator or physician-in-charge&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yataro Daigo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiga University of Medical Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiga University of Medical Science Hospital</name>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiga University</investigator_affiliation>
    <investigator_full_name>Yataro Daigo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

